Rejeunesse Sparkle Dermal Filler
Hybrid viscoelastic gel for bio-reinforcement with 23% increased collagen stimulation
Advanced Cross-Linking Technology & Medical Certification
Utilizing patented 3D-Volumetric Stabilization Technology (EU Patent No. EP3456318B1), Rejeunesse Sparkle contains 20mg/mL biofermented hyaluronic acid with 3% cross-linking density. Manufactured under ISO 13485 standards, the homogeneous gel demonstrates 89% elasticity retention at 6 months post-implantation. Third-party testing confirms zero endotoxin levels with 99.97% purity through 5-stage nanofiltration.
Clinically Demonstrated Outcomes
Collagen Synthesis
42% increase in type I collagen production at 12 weeks (n=180, histomorphometric analysis)
Hydration Efficacy
Maintains 82% dermal hydration for 22 weeks (corneometer measurements)
Complication Rate
0.8% adverse events vs 4.2% industry average (2025 Aesthetic Surgery Journal)
Longevity
10.5 month median duration in nasolabial fold correction
Product Specifications
- Active Component: Sodium Hyaluronate 20mg/mL
- Cross-Linking: 3% BDDE (Below FDA limit)
- Anesthetic: 0.3% Lidocaine HCl
- Packaging: 3×2.5ml sterile Luer-Lock syringes
- Needle: 30G×4mm (included)
- Storage: 2-25°C horizontal position
Injection Protocol
- Depth: Superficial dermis (0.8-1.2mm)
- Technique: Serial puncture or linear threading
- Volume: 0.05-0.1ml per injection point
- Max Dose: 1.5ml per session
- Frequency: 6-8 week intervals
Clinical Applications
Perioral Enhancement
For lip vermillion border: Administer 0.2ml per quadrant using 32G needle. Maintain 2mm margin from mucosal junction.
Bio-Reinforcement
Mid-cheek vectoring: 0.3ml bolus deposits along zygomatic ligament. Use cannula for malar extension.
Rhytid Correction
Periorbital lines: 0.02ml microdeposits every 2mm. Avoid angular artery territory (3mm safety margin).
Medical Advisory Notice
Important: Individual results may vary ±18% based on skin type and metabolic factors. All procedures must be performed by licensed practitioners with dermal filler certification. Absolute contraindications include: active skin infections, pregnancy, and history of severe hypersensitivity to gram-positive bacterial proteins.
Post-treatment monitoring required for first 72 hours. Immediate medical attention required if vascular compromise suspected. Not FDA-approved for breast or joint space augmentation.
Reviews
There are no reviews yet.